Article
Hematology
Tycel Phillips, Henry Chan, Constantine S. Tam, Alessandra Tedeschi, Patrick Johnston, Sung Yong Oh, Stephen Opat, Hyeon-Seok Eom, Heather Allewelt, Jennifer C. Stern, Ziwen Tan, William Novotny, Jane Huang, Judith Trotman
Summary: The study demonstrates favorable outcomes for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma treated with the selective Bruton's tyrosine kinase inhibitor zanubrutinib. The results support zanubrutinib as a potentially meaningful addition to available therapies for these patients.
Article
Oncology
Caron A. Jacobson, Julio C. Chavez, Alison R. Sehgal, Basem M. William, Javier Munoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, Henry Chi Hang Fung, Joseph Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu
Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.
Article
Hematology
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.
Article
Oncology
Yang Liu, Chunmeng Wang, Xiang Li, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Malcolm Brock, Miao Liu, Qian Mei, Jiejie Liu, Jing Nie, Weidong Han
Summary: The combination of camrelizumab and decitabine leads to longer progression-free survival in patients with relapsed/refractory cHL compared to camrelizumab monotherapy, showing superior efficacy and potential as a biomarker for treatment response in certain patient subgroups.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Oncology
Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang, Yidi Wang, Lei Wang, Tengfei Liu, Yun Zhang, Zhirong Shen, Jane Huang, Jun Zhu
Summary: This study presents the extended 3-year follow-up of tislelizumab in patients with relapsed/refractory cHL, showing long-term benefits and a favorable safety profile.
CLINICAL CANCER RESEARCH
(2022)
Article
Hematology
Christopher J. Forlenza, Nitya Gulati, Audrey Mauguen, Michael J. Absalon, Sharon M. Castellino, Anna Franklin, Frank G. Keller, Neerav Shukla
Summary: In this study, BVB was found to be well tolerated in pediatric patients with R/R HL and compared favorably with currently accepted salvage regimens, showing promising efficacy and outcomes in this population.
Article
Oncology
Paul J. Broeckelmann, Horst Mueller, Sarah Gillessen, Xiaoqin Yang, Larissa Koeppel, Veronika Pilz, Patricia Marinello, Peter Kaskel, Monika Raut, Michael Fuchs, Peter Borchmann, Andreas Engert, Bastian von Tresckow
Summary: Evaluation of rrHL patterns after first-line treatment revealed that high-dose chemotherapy and autologous stem-cell transplantation resulted in 10-year progression-free and overall survival rates of 48.2% and 59.4% respectively. Factors such as age and treatment failure significantly influenced patient survival rates.
Article
Oncology
Kenichi Ishizawa, Masahiro Yokoyama, Harumi Kato, Kazuhito Yamamoto, Masanori Makita, Kiyoshi Ando, Yasunori Ueda, Yoshimichi Tachikawa, Youko Suehiro, Mitsutoshi Kurosawa, Yoshihiro Kameoka, Hirokazu Nagai, Nobuhiko Uoshima, Takayuki Ishikawa, Michihiro Hidaka, Yoshikiyo Ito, Atae Utsunomiya, Koji Fukushima, Michinori Ogura
Summary: This study aimed to evaluate the safety and efficacy of bendamustine in different types of lymphoma patients. The results showed that bendamustine is safe, well-tolerated, and effective for previously untreated iNHL, MCL, or rrDLBCL patients.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Oncology
Marie Toukam, Jens Wuerthner, Karin Havenith, Mehdi Hamadani, Paolo F. Caimi, Tim Kopotsha, Hans G. Cruz, Joseph P. Boni
Summary: The purpose of this study was to develop a population pharmacokinetic (PPK) model to characterize the pharmacokinetics of camidanlumab tesirine (Cami) in patients with relapsed/refractory lymphoma. The final model obtained estimates of pharmacokinetic parameters and identified covariates that significantly affect Cami exposure.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Hematology
Eleonora Calabretta, Anna Guidetti, Francesca Ricci, Martina Di Trani, Chiara Monfrini, Massimo Magagnoli, Stefania Bramanti, Davide Maspero, Lucia Morello, Michele Merli, Alice Di Rocco, Alex Graudenzi, Enrico Derenzini, Marco Antoniotti, Davide Rossi, Paolo Corradini, Armando Santoro, Carmelo Carlo-Stella
Summary: Checkpoint inhibitors (CPIs) are commonly used in relapsed/refractory classical Hodgkin lymphoma, but long-term responses are uncommon and about one-third of patients remain refractory. This study analyzed the response to chemotherapy after CPI failure and characterized the clonal evolution in a small sample of patients. The results showed that most patients achieved complete remission and a small percentage achieved partial remission after chemotherapy rechallenge. Importantly, salvage chemotherapy followed by stem cell transplantation was an effective strategy for rescued CPI failure patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Nathan H. Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopinska-Posluszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech-Maranda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chavez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Michael S. Weiss, Pier Luigi Zinzani
Summary: Umbralisib demonstrated meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event-related discontinuations.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Hematology
Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Beth A. Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera
Summary: This study evaluated the combination of BV and Nivo as first salvage therapy for r/r cHL patients, showing high objective response rate and progression-free survival without additional toxicity concerns. Some patients were able to directly proceed to transplant after study treatment, indicating durable efficacy and impressive outcomes.
Article
Oncology
Marie Toukam, Joseph P. Boni, Mehdi Hamadani, Paolo F. Caimi, Hans G. Cruz, Jens Wuerthner
Summary: This study investigated the exposure-response relationships of Camidanlumab Tesirine (Cami) using an integrated population pharmacokinetic model. The results showed a significant positive relationship between exposure and overall response rate/overall survival, but this effect was non-significant in the final models due to covariate effects. Higher exposures of Cami were associated with a higher probability of experiencing grade >= 2 adverse events at cycle 6.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Hematology
Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muff Ly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen -Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai
Summary: The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has significantly changed over the past decade with the use of brentuximab vedotin (BV) and PD-1 inhibitors. A study comparing outcomes from 2011 to 2020 with those from 2001 to 2010 showed improved overall survival (OS) and increased postprogression survival in the modern era, attributed to the use of BV and PD-1 inhibitors. Factors associated with inferior progression-free survival (PFS) included age ≥45 years, primary refractory disease, and lack of complete remission pre-AHCT, while receipt of a PD-1 inhibitor-based regimen pre-AHCT was associated with superior PFS.
Article
Oncology
Alessandro Broccoli, Lisa Argnani, Paolo Elia Coppola, Marianna Gentilini, Gianmarco Bagnato, Ginevra Lolli, Matteo Carella, Laura Nanni, Alice Morigi, Beatrice Casadei, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani
Summary: After treatment with brentuximab vedotin, a proportion of patients who failed autologous stem cell transplantation for Hodgkin lymphoma can achieve and maintain long-term complete remission, indicating cure. The role of allogeneic transplantation in these patients is still being debated.
Review
Hematology
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M. H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. Park, James J. Wu, Rubina Siddiqi, John Reitan, Sally Wade, Gilles Salles
Summary: Relapsed Mantle cell lymphoma (MCL) has a poor prognosis and there is no standard treatment. This study examined the outcomes of salvage therapy in MCL patients who failed Bruton tyrosine kinase inhibitor (BTKi) therapy, showing shorter overall survival in this group compared to those who received post-BTKi therapy.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Carmelo Carlo-Stella, Pier Luigi Zinzani, Anna Sureda, Luis Araujo, Olivier Casasnovas, Cecilia Carpio, Su-Peng Yeh, Krimo Bouabdallah, Guillaume Cartron, Won Seog Kim, Raul Cordoba, Youngil Koh, Alessandro Re, Daniela Alves, Martine Chamuleau, Steven Le Gouill, Armando Lopez-Guillermo, Ilidia Moreira, Marjolein W. M. van der Poel, Giovanni Abbadessa, Robin Meng, Ran Ji, Lucie Lepine, Rao Saleem, Vincent Ribrag
Summary: This study evaluated the safety, efficacy, and pharmacokinetics of a combination treatment of Cemi (anti-PD-1 receptor antibody) and Isa (anti-CD38 antibody) in patients with relapsed or refractory lymphoma. The results showed that the combination treatment had manageable safety and modest clinical efficacy in patients with cHL, DLBCL, and PTCL.
HEMATOLOGICAL ONCOLOGY
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Lucia Zanoni, Davide Bezzi, Cristina Nanni, Andrea Paccagnella, Arianna Farina, Alessandro Broccoli, Beatrice Casadei, Pier Luigi Zinzani, Stefano Fanti
Summary: Non-Hodgkin lymphomas encompass a diverse group of lymphoproliferative disorders with varying clinical courses. 18F-FDG-PET/CT is the current gold standard diagnostic imaging for staging, restaging, and treatment evaluation in lymphomas with high glucose avidity. PET-based response criteria are now uniformly applied in FDG-avid lymphomas, and this article provides updates on the management of diffuse large B-cell lymphoma, follicular lymphoma, and other histotypes, as well as the use of PET-derived factors for patient stratification and prognostication, and emerging radiomics research. Published in Semin Nucl Med 53:320-351 (c) 2022 by Elsevier Inc.
SEMINARS IN NUCLEAR MEDICINE
(2023)
Article
Immunology
Serena De Matteis, Michele Dicataldo, Beatrice Casadei, Gianluca Storci, Noemi Laprovitera, Mario Arpinati, Enrico Maffini, Pietro Cortelli, Maria Guarino, Francesca Vaglio, Maria Naddeo, Barbara Sinigaglia, Luca Zazzeroni, Serafina Guadagnuolo, Enrica Tomassini, Salvatore Nicola Bertuccio, Daria Messelodi, Manuela Ferracin, Massimiliano Bonafe, Pier Luigi Zinzani, Francesca Bonifazi
Summary: Inflammatory complications, such as ICANS, can affect the infusion of CAR T cells in patients with R/R-BCL. This study found that a lower percentage of CD3(+)CD8(+) lymphocytes and higher levels of CRP were associated with ICANS. Additionally, ICANS patients had an increase in senescent CD8(+) T cells and M-MDSC, as well as elevated levels of EVs carrying myeloid markers and cytokines.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Maria Rescigno, Chiara Agrati, Carlo Salvarani, Diana Giannarelli, Massimo Costantini, Alberto Mantovani, Raffaella Massafra, Pier Luigi Zinzani, Aldo Morrone, Stefania Notari, Giulia Matusali, Giuseppe Lauria Pinter, Antonio Uccelli, Gennaro Ciliberto, Fausto Baldanti, Franco Locatelli, Nicola Silvestris, Valentina Sinno, Elena Turola, Maria Teresa Lupo-Stanghellini, Giovanni Apolone
Summary: This study compared the B-cell, T-cell, and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus in patients with hematological malignancies, solid tumors, and immune-rheumatological diseases after the fourth dose of mRNA COVID-19 vaccine. The T-cell response was similarly boosted by the fourth dose across different subgroups, while the antibody response was improved only in patients not receiving B-cell targeted therapies. However, a small percentage of patients did not have neutralizing antibodies to either virus variants, making them vulnerable to SARS-CoV-2 infection. The increment of neutralizing antibodies was similar towards Omicron BA.2 and WT virus after the third or fourth dose of vaccine. Additional booster doses are recommended for frail patients to enhance the development of a B-cell response against Omicron and/or to enhance the T-cell response in patients treated with anti-CD20.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.
Article
Hematology
Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, A. Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Ozcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand
Summary: Previous analysis of the KEYNOTE-170 study showed that pembrolizumab was effective and safe in treating relapsed/refractory PMBCL patients who had disease progression after autologous stem cell transplantation or were ineligible for the procedure. The final analysis revealed that after 4 years of follow-up, pembrolizumab still demonstrated durable responses and promising trends for long-term survival, with acceptable safety.
Article
Oncology
Marianna Gentilini, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Marco Ferrari, Matteo Carella, Lisa Argnani, Pier Luigi Zinzani
Summary: Endobronchial localization of Hodgkin lymphoma is rare and there have been few reports in the literature since the 1900s. This study presents the first case of a relapsed/refractory Hodgkin lymphoma patient with a critical vegetative mass at the level of the trachea, successfully treated with pembrolizumab.
Article
Pharmacology & Pharmacy
Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea
Summary: CAR T-cell therapy may cause cytokine release syndrome (CRS) and acute kidney injury, potentially affecting the pharmacokinetics of beta-lactam drugs. This study found that the clearance of meropenem and piperacillin did not need to be reduced in CAR T-cell patients experiencing CRS.
Article
Hematology
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz
Summary: The combination therapy of nivolumab and brentuximab vedotin showed long-term efficacy in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL), suggesting potential clinical applications.
Article
Hematology
Livio Pagano, Pier Luigi Zinzani, Stefano Pileri, Pietro Quaglino, Branko Cuglievan, Emilio Berti, Naveen Pemmaraju, Francesco Onida, Rein Willemze, Alberto Orfao, Giovanni Barosi
Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with recurrent skin nodules, aggressive clinical course, and poor prognosis. Due to its rarity, there is limited research, lack of controlled clinical trials, and absence of evidence-based guidelines for its management. This review presents recommendations and proposals by a panel of experts to address the unmet clinical needs in the management of BPDCN. The hope is that this comprehensive overview will improve the practice of BPDCN and guide future studies in the field.
Article
Oncology
Mehdi Hamadani, Morton Coleman, Ralph Boccia, Juraj Duras, Martin Hutchings, Pier Luigi Zinzani, Raul Cordoba, Mariana Bastos Oreiro, Vanessa Williams, Huiqing Liu, Michael Stouffs, Peter Langmuir, Juan-Manuel Sancho
Summary: The combination of parsaclisib with obinutuzumab and bendamustine showed promising clinical benefit in patients with relapsed or refractory follicular lymphoma, without unexpected safety events.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Hematology
Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M. Linton, Pamela Mckay, Sophie Leitch, Morton Coleman, Pier Luigi Zinzani, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Peter Browett, Xiaoyan Ke, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A. Hawkes, Shir-Jing Ho, Keshu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Summary: The final analysis of MAGNOLIA demonstrated that zanubrutinib provided sustained clinical responses and favorable safety/tolerability in patients with relapsed/refractory marginal zone lymphoma.
Article
Hematology
Stephen M. Ansell, Paul J. Brockelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trneny, Mariano Provencio, Ulrich Jaeger, Wolfgang Willenbacher, Rachael Wen, Alev Akyol, Joanna Mikita-Geoffroy, Margaret A. Shipp, Andreas Engert, Philippe Armand
Summary: This study demonstrates that nivolumab provides frequent and durable responses in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation failure. Results suggest that treatment can be discontinued after persistent complete remission and resumed upon disease progression.